Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) Research & Development (2021 - 2025)

Krystal Biotech's Research & Development history spans 5 years, with the latest figure at $14.8 million for Q4 2025.

  • For Q4 2025, Research & Development rose 9.35% year-over-year to $14.8 million; the TTM value through Dec 2025 reached $58.0 million, up 8.33%, while the annual FY2025 figure was $58.0 million, 8.33% up from the prior year.
  • Research & Development for Q4 2025 was $14.8 million at Krystal Biotech, up from $14.6 million in the prior quarter.
  • Across five years, Research & Development topped out at $15.6 million in Q2 2024 and bottomed at $6.1 million in Q3 2021.
  • The 5-year median for Research & Development is $11.4 million (2022), against an average of $11.4 million.
  • The largest annual shift saw Research & Development surged 89.41% in 2022 before it dropped 10.83% in 2024.
  • A 5-year view of Research & Development shows it stood at $9.0 million in 2021, then increased by 19.23% to $10.7 million in 2022, then grew by 5.87% to $11.4 million in 2023, then rose by 18.98% to $13.5 million in 2024, then grew by 9.35% to $14.8 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Research & Development are $14.8 million (Q4 2025), $14.6 million (Q3 2025), and $14.4 million (Q2 2025).